Cargando…

Oropharyngeal Probiotic ENT-K12 Prevents Respiratory Tract Infections Among Frontline Medical Staff Fighting Against COVID-19: A Pilot Study

Healthcare workers at the frontline are facing a substantial risk of respiratory tract infection during the COVID-19 outbreak due to an extremely stressful work schedule and public health event. A well-established first-line defense on oropharyngeal microbiome could be a promising strategy to protec...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qiang, Lin, Xuan, Xiang, Xiaochen, Liu, Wanxin, Fang, Ying, Chen, Haiping, Tang, Fang, Guo, Hongyan, Chen, Di, Hu, Xiafen, Wu, Qingming, Zhu, Baoli, Xia, Junbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264449/
https://www.ncbi.nlm.nih.gov/pubmed/34249878
http://dx.doi.org/10.3389/fbioe.2021.646184
_version_ 1783719559466844160
author Wang, Qiang
Lin, Xuan
Xiang, Xiaochen
Liu, Wanxin
Fang, Ying
Chen, Haiping
Tang, Fang
Guo, Hongyan
Chen, Di
Hu, Xiafen
Wu, Qingming
Zhu, Baoli
Xia, Junbo
author_facet Wang, Qiang
Lin, Xuan
Xiang, Xiaochen
Liu, Wanxin
Fang, Ying
Chen, Haiping
Tang, Fang
Guo, Hongyan
Chen, Di
Hu, Xiafen
Wu, Qingming
Zhu, Baoli
Xia, Junbo
author_sort Wang, Qiang
collection PubMed
description Healthcare workers at the frontline are facing a substantial risk of respiratory tract infection during the COVID-19 outbreak due to an extremely stressful work schedule and public health event. A well-established first-line defense on oropharyngeal microbiome could be a promising strategy to protect individuals from respiratory tract infections including COVID-19. The most thoroughly studied oropharyngeal probiotic product which creates a stable upper respiratory tract microbiota capable of preventing upper respiratory tract infections was chosen to evaluate the safety and efficacy on reducing episodes of upper respiratory tract infections for COVID-19 healthcare workers. To our knowledge to date, this is the very first study describing the beneficial effects of oropharyngeal probiotic been administered by healthcare workers during the COVID-19 pandemic. In this randomized controlled trial, we provided the probiotics to frontline medical staff who work in the hospitals in Wuhan and had been in close contact with hospitalized COVID-19 patients for prophylactic use on a daily basis. Our finding suggests that oropharyngeal probiotic administration significantly reduced the incidence of respiratory tract infections by 64.8%, reduced the time experiencing respiratory tract infections and oral ulcer symptoms by 78%, shortened the days absent from work by 95.5%, and reduced the time under medication where there is no record of antibiotic and anti-viral drug intake in the probiotic group. Furthermore, medical staff treated with Bactoblis experienced sustained protection from respiratory tract infections since the 10th day of oropharyngeal probiotic administration resulting in an extremely low incidence rate of respiratory tract infections.
format Online
Article
Text
id pubmed-8264449
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82644492021-07-09 Oropharyngeal Probiotic ENT-K12 Prevents Respiratory Tract Infections Among Frontline Medical Staff Fighting Against COVID-19: A Pilot Study Wang, Qiang Lin, Xuan Xiang, Xiaochen Liu, Wanxin Fang, Ying Chen, Haiping Tang, Fang Guo, Hongyan Chen, Di Hu, Xiafen Wu, Qingming Zhu, Baoli Xia, Junbo Front Bioeng Biotechnol Bioengineering and Biotechnology Healthcare workers at the frontline are facing a substantial risk of respiratory tract infection during the COVID-19 outbreak due to an extremely stressful work schedule and public health event. A well-established first-line defense on oropharyngeal microbiome could be a promising strategy to protect individuals from respiratory tract infections including COVID-19. The most thoroughly studied oropharyngeal probiotic product which creates a stable upper respiratory tract microbiota capable of preventing upper respiratory tract infections was chosen to evaluate the safety and efficacy on reducing episodes of upper respiratory tract infections for COVID-19 healthcare workers. To our knowledge to date, this is the very first study describing the beneficial effects of oropharyngeal probiotic been administered by healthcare workers during the COVID-19 pandemic. In this randomized controlled trial, we provided the probiotics to frontline medical staff who work in the hospitals in Wuhan and had been in close contact with hospitalized COVID-19 patients for prophylactic use on a daily basis. Our finding suggests that oropharyngeal probiotic administration significantly reduced the incidence of respiratory tract infections by 64.8%, reduced the time experiencing respiratory tract infections and oral ulcer symptoms by 78%, shortened the days absent from work by 95.5%, and reduced the time under medication where there is no record of antibiotic and anti-viral drug intake in the probiotic group. Furthermore, medical staff treated with Bactoblis experienced sustained protection from respiratory tract infections since the 10th day of oropharyngeal probiotic administration resulting in an extremely low incidence rate of respiratory tract infections. Frontiers Media S.A. 2021-06-24 /pmc/articles/PMC8264449/ /pubmed/34249878 http://dx.doi.org/10.3389/fbioe.2021.646184 Text en Copyright © 2021 Wang, Lin, Xiang, Liu, Fang, Chen, Tang, Guo, Chen, Hu, Wu, Zhu and Xia. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Wang, Qiang
Lin, Xuan
Xiang, Xiaochen
Liu, Wanxin
Fang, Ying
Chen, Haiping
Tang, Fang
Guo, Hongyan
Chen, Di
Hu, Xiafen
Wu, Qingming
Zhu, Baoli
Xia, Junbo
Oropharyngeal Probiotic ENT-K12 Prevents Respiratory Tract Infections Among Frontline Medical Staff Fighting Against COVID-19: A Pilot Study
title Oropharyngeal Probiotic ENT-K12 Prevents Respiratory Tract Infections Among Frontline Medical Staff Fighting Against COVID-19: A Pilot Study
title_full Oropharyngeal Probiotic ENT-K12 Prevents Respiratory Tract Infections Among Frontline Medical Staff Fighting Against COVID-19: A Pilot Study
title_fullStr Oropharyngeal Probiotic ENT-K12 Prevents Respiratory Tract Infections Among Frontline Medical Staff Fighting Against COVID-19: A Pilot Study
title_full_unstemmed Oropharyngeal Probiotic ENT-K12 Prevents Respiratory Tract Infections Among Frontline Medical Staff Fighting Against COVID-19: A Pilot Study
title_short Oropharyngeal Probiotic ENT-K12 Prevents Respiratory Tract Infections Among Frontline Medical Staff Fighting Against COVID-19: A Pilot Study
title_sort oropharyngeal probiotic ent-k12 prevents respiratory tract infections among frontline medical staff fighting against covid-19: a pilot study
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264449/
https://www.ncbi.nlm.nih.gov/pubmed/34249878
http://dx.doi.org/10.3389/fbioe.2021.646184
work_keys_str_mv AT wangqiang oropharyngealprobioticentk12preventsrespiratorytractinfectionsamongfrontlinemedicalstafffightingagainstcovid19apilotstudy
AT linxuan oropharyngealprobioticentk12preventsrespiratorytractinfectionsamongfrontlinemedicalstafffightingagainstcovid19apilotstudy
AT xiangxiaochen oropharyngealprobioticentk12preventsrespiratorytractinfectionsamongfrontlinemedicalstafffightingagainstcovid19apilotstudy
AT liuwanxin oropharyngealprobioticentk12preventsrespiratorytractinfectionsamongfrontlinemedicalstafffightingagainstcovid19apilotstudy
AT fangying oropharyngealprobioticentk12preventsrespiratorytractinfectionsamongfrontlinemedicalstafffightingagainstcovid19apilotstudy
AT chenhaiping oropharyngealprobioticentk12preventsrespiratorytractinfectionsamongfrontlinemedicalstafffightingagainstcovid19apilotstudy
AT tangfang oropharyngealprobioticentk12preventsrespiratorytractinfectionsamongfrontlinemedicalstafffightingagainstcovid19apilotstudy
AT guohongyan oropharyngealprobioticentk12preventsrespiratorytractinfectionsamongfrontlinemedicalstafffightingagainstcovid19apilotstudy
AT chendi oropharyngealprobioticentk12preventsrespiratorytractinfectionsamongfrontlinemedicalstafffightingagainstcovid19apilotstudy
AT huxiafen oropharyngealprobioticentk12preventsrespiratorytractinfectionsamongfrontlinemedicalstafffightingagainstcovid19apilotstudy
AT wuqingming oropharyngealprobioticentk12preventsrespiratorytractinfectionsamongfrontlinemedicalstafffightingagainstcovid19apilotstudy
AT zhubaoli oropharyngealprobioticentk12preventsrespiratorytractinfectionsamongfrontlinemedicalstafffightingagainstcovid19apilotstudy
AT xiajunbo oropharyngealprobioticentk12preventsrespiratorytractinfectionsamongfrontlinemedicalstafffightingagainstcovid19apilotstudy